Biodistribution of polysorbate 80-coated doxorubicin-loaded [¹⁴C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats

References

• Alyautdin RN, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin absorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 1995; 41: 44–48
   Web of Science ®Google Scholar
• Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood–brain barrier with polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Pharm Res 1997; 14: 325–328
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles: An in situ brain perfusion study. J Microencapsul 1998; 15: 67–74
   PubMed Web of Science ®Google Scholar
• Ambruosi A, Hiromitsu Y, Kreuer J. Body distribution of polysorbate-80 and doxorubicin-loaded (14C-poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J Drug Target 13 2005; 535–542
   Google Scholar
• Araujo L, Lobenberg R, Kreuter J. Influence of the surfactant concentration on the body distribution of nanoparticles. J Drug Target 1999; 6: 373–385
   PubMed Web of Science ®Google Scholar
• Begley DJ. The blood–brain barrier: Principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 1996; 48: 136–146
   PubMed Web of Science ®Google Scholar
• Begley DJ. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharm Ther 2004; 104: 29–45
   PubMed Web of Science ®Google Scholar
• Buahin KG, Brem H. Interstitial chemotherapy of experimental brain tumors: Comparison of intratumoral injection versus polymeric controlled release. J Neurooncol 1995; 26: 103–110, Brandes AA, Pasetto LM, Monfardini S. 2000. New drugs in recurrent high grade gliomas. Anticancer Res 20: 1913–1920
   PubMed Web of Science ®Google Scholar
• Bonstelle CT, Kori SH, Rekate H. Intracarotid chemotherapy of glioblastoma after induced blood–brain barrier disruption. AJNR Am J Neuroradiol 1983; 4: 810–812
   PubMed Web of Science ®Google Scholar
• Borchard G, Kreuter J. Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. J Drug Target 1993; 1: 15–19
   PubMed Web of Science ®Google Scholar
• Brigger I, Morizet J, Aubert G, Chacun H, Terrier-Lacombe MJ, Couvreur P, Vassal G. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther 2002; 303: 928–936
   PubMed Web of Science ®Google Scholar
• Brigger I, Morizet J, Couvreur P. Negative preclinical results with stealth nanospheres-encapsulated doxorubicin in an orthotopic murine brain tumor model. J Control Release 2004; 100: 29–40
   PubMed Web of Science ®Google Scholar
• Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE, Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett 2002; 126: 131–141
   PubMed Web of Science ®Google Scholar
• Granholm AC, Albeck D, Backman C, Curtis M, Ebendal T, Friden P, Henry M, Hoffer B, Kordower J, Rose GM, Soderstrom S, Bartus RT. A non-invasive system for delivering neural growth factors across the blood–brain barrier: A review. Rev Neurosci 1998; 9: 31–55
   PubMed Web of Science ®Google Scholar
• Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999; 16: 1564–1569
   PubMed Web of Science ®Google Scholar
• Ji Y, Powers SK, Brown JT, Miner R. Characterization of the tumour invasion area in the rat intracerebral glioma. J Neuro-Oncol 1996; 30: 189–197
   PubMed Web of Science ®Google Scholar
• Kreuter J. Physicochemical characterization of polyacrylic nanoparticles. Int J Pharm 1983; 14: 43–58
   Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65–81
   PubMed Web of Science ®Google Scholar
• Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ. Direct evidence that polysorbate-80-coated poly(butyl cyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20: 409–416
   PubMed Web of Science ®Google Scholar
• Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev Ind Pharm 2002; 28: 1–13
   PubMed Web of Science ®Google Scholar
• Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989; 6: 193–210
   PubMed Web of Science ®Google Scholar
• Maeda H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46: 169–185
   PubMed Web of Science ®Google Scholar
• Moos T, Mølgård K. Cerebrovascular permeability to azo dyes and plasma proteins. Neuropath Appl Neurobiol 1993; 19: 120–127
   PubMed Web of Science ®Google Scholar
• Neuwelt E. Mechanisms of disease: The blood–brain barrier. Neurosurgery 2004; 54: 131–140
   PubMed Web of Science ®Google Scholar
• Nomura T, Inamura T, Black KL. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res 1994; 659: 62–66
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood–brain barrier drug targeting: The future of brain drug development. Mol Interv 2003; 3(90–105)51
   Google Scholar
• Prabhu SS, Broaddus WC, Oveissi C, Berr SS, Gillies GT. Determination of intracranial tumor volumes in a rodent brain using magnetic resonance imaging, Evans Blue, and histology: A comparative study. IEEE Trans Biomed Eng 2000; 47: 259–265
   PubMed Web of Science ®Google Scholar
• Schaller B. Usefulness of positron emission tomography in diagnosis and treatment follow-up of brain tumors. Neurobiol Dis 2004; 15: 437–448
   PubMed Web of Science ®Google Scholar
• Shimura T, Teramoto A, Nakazawa S, Aihara K. A clinicopathological study of malignant glioma done after local administration of chemotherapeutic agents. Clin Neuropathol 1996; 15: 119–124
   PubMed Web of Science ®Google Scholar
• Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004; 109: 759–767
   PubMed Web of Science ®Google Scholar
• Tröster SD, Müller U, Kreuter J. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int J Pharm 1990; 61: 85–100
   Web of Science ®Google Scholar
• Tsuji A. Specific mechanism for transporting drugs into the brain. The blood–brain barrier and the drug delivery to the CNS, DJ Begley, MW Bradbury, J Kreuter. Marcel Dekker, New York 2000; 121–144
   Google Scholar
• Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N, Newcomb EW. Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 2003; 196: 394–402
   PubMed Web of Science ®Google Scholar